 Madrigal Pharmaceuticals NASDAQ: MDGL stock is rocketing higher on Monday after sharing results from its novel therapeutics for nonalcoholic steatohepatitis NASH treatment. The company reported positive topline results, including both liver histological improvement endpoints, proposed by the U.S. Food and Drug Administration FDA. 